Form 4: Daxor Director Henry Cremisi Granted 2,500 Stock Options Contingent on SEC Plan Approval

Daxor Corp. Director Henry D. Cremisi was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Summary

• Henry D. Cremisi, a Director and 10% Owner of Daxor Corp. (DXR), was granted 2,500 stock options.
• The stock options have an exercise price of $9.29 per share.
• The grant date for these options is June 24, 2025, and they expire on June 24, 2030.
• The grant is contingent upon the Securities & Exchange Commission (SEC) approving an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• The options will vest in three annual installments: 833 options on June 24, 2025, 883 options on June 24, 2026, and 834 options on June 24, 2027.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally positive as it aligns interests. However, the contingency on SEC approval introduces a minor element of uncertainty, preventing a higher score.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $9.29 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• The stock option grant is contingent on SEC approval of an amendment to the 2020 Incentive Compensation Plan, introducing a condition that must be met for the grant to be finalized.

Risks

• The primary risk is that the SEC may not approve the amendment to the Daxor Corporation 2020 Incentive Compensation Plan, which would prevent the stock option grant from becoming effective.

Future Outlook

The future outlook for this specific grant is dependent on the Securities & Exchange Commission's approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan. If approved, the options will vest in three annual tranches through June 2027.

Industry Context

The granting of stock options to directors is a common practice in publicly traded companies across various industries. It serves as a form of incentive compensation designed to align the interests of directors with those of shareholders by tying their compensation to the company's stock performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice, similar to what is observed in many public companies globally.
• The specific number of options (2,500) and the exercise price ($9.29) are specific to Daxor Corp. and would need comparison against peer companies of similar market capitalization and industry to assess their relative size and value within typical compensation packages. No specific comparable companies or projects are mentioned in the document to facilitate a direct comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased alignment of director interests with shareholder value creation.
• Employees: The amendment to the 2020 Incentive Compensation Plan could affect the broader employee incentive structure, though this specific filing only details a director's grant.

Next Steps

• Daxor Corporation will await the Securities & Exchange Commission's approval of the amendment to its 2020 Incentive Compensation Plan.
• Upon approval, the stock options will begin vesting according to the specified schedule on June 24, 2025, June 24, 2026, and June 24, 2027.

Key Dates

Keywords

Daxor Corp, DXR, SEC Form 4, Stock Options, Director Compensation, Incentive Compensation Plan, Beneficial Ownership, Corporate Governance